VOGO-0.2 15'S

About

Voglibose 0.2mg is an oral antidiabetic agent belonging to the class of alpha-glucosidase inhibitors, primarily utilized for the management of type 2 diabetes mellitus. Its therapeutic action involves selectively inhibiting the enzymes alpha-glucosidase in the brush border of the small intestine. This inhibition slows down the enzymatic breakdown of complex carbohydrates, such as starch and disaccharides, into absorbable monosaccharides like glucose. Consequently, the rate of glucose absorption into the bloodstream is attenuated, leading to a significant reduction in postprandial blood glucose spikes. Voglibose is particularly beneficial for patients who experience pronounced hyperglycemia after meals. It is typically prescribed as an adjunct to dietary modifications and exercise, and can be used as monotherapy or in combination with other oral hypoglycemic agents or insulin.

Uses

• To manage type 2 diabetes mellitus.
• To reduce elevated postprandial blood glucose levels.
• As a complementary therapy to diet and exercise.
• For individuals with impaired glucose tolerance to prevent diabetes progression.

Directions For Use

Take one tablet (0.2mg) orally three times a day, immediately before each main meal.

Benefits

• Effectively controls post-meal blood sugar elevations.
• Helps improve overall glycemic control.
• Lowers the risk of long-term diabetic complications.
• Can be safely combined with other antidiabetic medications.
• Minimal risk of weight gain.
• Reduces the burden on pancreatic beta cells.

Side Effects

• Abdominal distension
• Flatulence
• Diarrhea
• Abdominal pain
• Nausea
• Vomiting
• Heartburn
• Constipation
• Skin rash
• Headache
• Dizziness
• Hypoglycemia (rare, especially when used alone)

Safety Measures

• Alcohol - Alcohol can influence blood glucose levels; consume with caution and monitor blood sugar.
• Pregnancy - Avoid during pregnancy; consult a doctor for appropriate management.
• Breastfeeding - Avoid during breastfeeding; seek medical advice for alternatives.
• Liver - Exercise caution in patients with severe hepatic impairment; liver function tests should be monitored.
• Kidney - Exercise caution in patients with severe renal impairment; dose adjustment may be necessary.
• Lung - Generally considered safe for patients with lung conditions; no specific contraindications.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.